Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.96 |
| ▸ | BLM | P54132 | 6/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | APEX1 | P27695 | 4/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norepinephrine SCHEMBL29399946 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2429869 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29371849 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29460319 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2609 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL2610 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL3489077 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL4155242 | 0.96 | BLM (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL10576062 | 0.96 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL17504429 | 0.96 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315493-A4 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | UNIV GEORGETOWN (US) | 2007-12-05 | — | — | EP | claimed |
| US-20050131051-A1 | 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon | WANG SHAOMENG (US) | 2005-06-16 | — | — | US | claimed |
| EP-1315493-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2003-06-04 | — | — | EP | claimed |
| WO-2002015906-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2002-02-28 | — | — | WO | claimed |
| CN-119100941-A | Preparation and application of contracture medicine with synergistic antidepressant effect and composition thereof | 江苏海洋大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-115385914-B | Application of ligand small molecule of targeting PDCD4 in preparation of antidepressant drugs | 山东大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024081853-A2 | MONOAMINE OXIDASE (MAO) ELECTROCHEMICAL BIOSENSOR AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-117815288-A | Probiotic composition and probiotic granule for adjusting emotion, and preparation method and application thereof | 黑龙江灵泰健康科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2022246930-A1 | APPLICATION OF LIGAND SMALL MOLECULE TARGETING PDCD4 IN PREPARATION OF ANTIDEPRESSANT DRUGS | 山东大学 | 2022-12-01 | — | — | WO | disclosed |
| CN-115385914-A | Application of ligand small molecule of targeting PDCD4 in preparation of antidepressant drugs | 山东大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-109497342-A | It is a kind of for preventing and treating the feed addictive of chicken diarrhea | 鼎正动物药业（天津）有限公司 | 2019-03-22 | — | — | CN | disclosed |
| US-9149469-B2 | Pharmaceutical composition and a process thereof | INDUS BIOTECH PVT. LTD. (IN) | 2015-10-06 | — | — | US | disclosed |
| CN-1549709-A | Use of a class of antiviral compounds in the manufacture of a formulation for the treatment or prevention of viral infections in the respiratory tract | ����ɯ�ס����ڵ��ɿ� | 2004-11-24 | — | — | CN | disclosed |
| CN-1539497-A | Combinaton of medication for treating depression and preparation method | �Ϻ���ͨ��ѧ | 2004-10-27 | — | — | CN | disclosed |
| US-20040171624-A1 | Pharmaceutical composition for treating mood disorders | TAIYO KAGAKU CO, LTD. (JP) | 2004-09-02 | — | — | US | disclosed |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1315493-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2003-06-04 | — | — | EP | disclosed |
| CN-1401381-A | Antidepressant composition and preparation method thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002015906-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PTGES2, PTGS2, PTGER2 | ADRB2 212/4885ADRB1 824/4885ADRA2A 449/4885 |
| US-20050131051-A1 | 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon | SLC6A3, SLC6A2, SLC6A4 | ADRB2 35/4885ADRB1 63/4885ADRA2A 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.